MARATTO

article · American Journal of Internal Medicine

Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo

Abstract

Background and aims: the whole of humanity has experienced since December 2019 a pandemic of coronavirus disease 2019 , caused by the coronavirus. Unprecedented situation in this century especially for the DR Congo with a less equipped health system. The objective of this study is to describe the clinico-biological profile of patients hospitalized at the Cinquantenaire Hospital of Kinshasa in DR Congo. Methods: This was a retrospective, analytical and descriptive cohort study carried out among 360 patients hospitalized at the Cinquantenaire Hospital in Kinshasa from the period from April 18, 2020 to July 10, 2021. Results: The average age was 42.7 12.0 years with a female predominance, 57.7% of patients were over 50 years old. Comorbidities such as hypertension, diabetes mellitus and bronchial asthma were present respectively in 25.2% and 4.2% and 12.3%. The symptomatology was dominated by cough, fever and asthenia in more than The most common biological abnormalities were as follows: increased CRP (57.7%), basocytaemia (55%), hepatic cytolysis (20.6%), elevated D-dimer (15.3%), decreased TP (17.5%) lymphopenia (16.7%), anemia (11.1%) and Hyperleukocytosis 10.6% Conclusion: COVID-19 infection should be considered as sepsis with multi-visceral involvement although the lung is first. Both biological and hematological abnormalities may be encountered.

Research topics

  • COVID-19 Clinical Research Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.11648/j.ajim.20221003.14

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.